威斯科特-奥尔德里奇综合征相关疾病导致的严重湿疹经度普利尤单抗治疗后得到成功缓解。
Severe eczema in Wiskott-Aldrich syndrome-related disorder successfully treated with dupilumab.
机构信息
Division of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Mayo Clinic College of Medicine and Science, Scottsdale, Arizona, USA.
出版信息
Pediatr Dermatol. 2024 Jan-Feb;41(1):143-144. doi: 10.1111/pde.15397. Epub 2023 Jul 19.
Treatment of severe eczema in patients with primary immunodeficiencies can be particularly challenging as there are no guidelines with regards to these conditions. Dupilumab is an interleukin (IL)-4Rα antagonist that inhibits both IL-4 and IL-13 and is approved for the treatment of atopic dermatitis in pediatric patients. In this report, we describe a patient with a case of severe eczema in the context of Wiskott-Aldrich syndrome-related disorder, who was successfully treated with dupilumab.
对于原发性免疫缺陷患者的严重湿疹的治疗可能极具挑战性，因为针对这些病症并没有相关的指导原则。度普利尤单抗是一种白细胞介素（IL）-4Rα拮抗剂，可同时抑制 IL-4 和 IL-13，已被批准用于治疗儿科患者的特应性皮炎。在本报告中，我们描述了一例患有威斯科特-奥尔德里奇综合征相关疾病的严重湿疹患者，该患者使用度普利尤单抗成功治疗。
Zotero 插件